Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24439171 | 0.85 | FUCA1 (0.49) | ACHEFUCA1DRD2DRD3SIGMAR1 | |
| SCHEMBL21737903 | 0.83 | ACHE (0.58) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL26709643 | 0.83 | ACHE (0.58) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL3212351 | 0.83 | ACHE (0.58) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL12181407 | 0.83 | ACHE (0.44) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL11413096 | 0.82 | FUCA1 (0.60) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL16837173 | 0.81 | FUCA1 (0.58) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL67177 | 0.81 | FUCA1 (0.60) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL16497736 | 0.81 | FUCA1 (0.47) | ACHEFUCA1DRD2DRD3BCHE | |
| SCHEMBL46428 | 0.81 | FUCA1 (0.60) | ACHEFUCA1DRD2DRD3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796470-B2 | Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294854-A1 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS | ORAI1, CACNA1E, RYR1 | ACHE 684/4885FUCA1 4840/4885DRD2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.